| アブストラクト | INTRODUCTION: We compared the real-world effectiveness of initiating beclometasone dipropionate/formoterol fumarate (BDP/FOR) versus fluticasone furoate/vilanterol (FF/VI) in a general practice (GP) asthma cohort in England. METHODS: Patients newly initiating BDP/FOR or FF/VI between 1 December 2015 and 28 February 2019 (index), were selected from anonymised Clinical Practice Research Datalink data. Baseline was < 12 months pre-index with </= 12 months follow-up post-index. Eligible patients were aged >/= 18 years at index, had diagnosed asthma, >/= 1 FF/VI or BDP/FOR prescription, medical records eligible for linkage to secondary care data and continuous GP-registration >/= 12 months pre-index. Patients with chronic obstructive pulmonary disease, >/= 1 fixed-dose inhaled corticosteroid/long-acting beta(2)-agonist, single-inhaler triple or biologic therapy at index were excluded. The primary study outcome was asthma exacerbation rate. Secondary outcomes included medication persistence and oral corticosteroid (OCS) use. Propensity scores were generated for each treatment comparison; inverse probability of treatment weighting adjusted for confounding in baseline characteristics between groups, applied to each outcome separately. Analyses considered intercurrent events (ICEs; treatment switching, discontinuation, loss to follow-up, death, rescue medication use). RESULTS: Weighted group standard mean differences showed adequate balance for most covariates. Patients initiating BDP/FOR (n = 46,809) and FF/VI (n = 3773) had numerically similar exacerbation rates per person per year (PPPY) while-on index treatment [measuring outcome until ICE; BDP/FOR, 0.1479 (n = 31,715); FF/VI, 0.1338 (n = 2547); rate ratio 0.9048, p = 0.2841]. Patients continuing uninterrupted index treatment for 12 months had a lower exacerbation rate PPPY for FF/VI [0.0681 (n = 384)] than BDP/FOR [0.1104 (n = 3342); rate ratio, 0.6162 (p = 0.0293)]. For patients initiating FF/VI versus BDP/FOR, treatment persistence was greater [hazard ratio, 0.76 (p < 0.0001)]. CONCLUSION: Overall, patients initiating FF/VI and BDP/FOR had numerically similar exacerbation rates; of the patients continuing 12 months' uninterrupted treatment, the FF/VI group had a lower exacerbation rate versus BDP/FOR. Patients initiating FF/VI were less likely to discontinue treatment than those initiating BDP/FOR. |
|---|
| 投稿者 | Woodcock, Ashley; Blakey, John; Bourdin, Arnaud; Canonica, Giorgio Walter; Domingo, Christian; Ford, Alexander; Hulme, Rosie; Tritton, Theo; Palomares, Ines; Sadhu, Sanchayita; Biswas, Arunangshu; Verma, Manish |
|---|
| 組織名 | Division of Infection, Immunity and Respiratory Medicine, Manchester Academic;Health Sciences Centre, The University of Manchester and Manchester University;NHS Foundation Trust, Greater Manchester, UK.;Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia.;Medical School, Curtin University, Perth, WA, Australia.;Department of Respiratory Diseases, INSERM U1046, University of Montpellier,;Montpellier, France.;Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini;4, Pieve Emanuele, 20072, Milan, Italy.;Personalized Medicine Asthma & Allergy Unit, IRCCS Humanitas Research Hospital,;Via Manzoni 56, Rozzano, 20089, Milan, Italy.;Department of Pulmonary Medicine, Parc Tauli Hospital Universitari, Institut;d'Investigacio i Innovacio Parc Tauli (I3PT-CERCA), Universitat Autonoma de;Barcelona, Sabadell, Spain.;Adelphi Real World, Bollington, UK.;RWE & Health Outcomes Research, Global Health, GSK, Madrid, Spain.;Biostatistics, GSK, Bangalore, India.;Global Medical Affairs, General Medicine, GSK, GSK House, Dr. Annie Besant Road,;Worli, Mumbai, 400030, India. manish.8.verma@gsk.com. |
|---|
